GLSI · CIK 0001799788
What Greenwich LifeSciences, Inc. told the SEC could break it.
Greenwich LifeSciences is a clinical-stage company with no revenue and a single product candidate, so its future success depends entirely on FDA approval of GP2. That bet narrows further at the supply level — it relies on a single manufacturer for GM-CSF, a key component of the GP2 immunotherapy, for both its ongoing trials and any commercialization. It is also heavily dependent on a small senior team led by CEO Snehal Patel and carries no key-person life insurance, and it flags a related-party arrangement: expense reimbursements to Mr. Patel and two family members contracted or employed by the company totaled about $3.8 million in 2025, up from roughly $1.8 million in 2024.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA approval of single product candidate (GP2)high
As a clinical-stage company with one product candidate and no revenue, future success depends entirely on FDA regulatory approval of GP2.
“Our future success is dependent on the regulatory approval of our product candidate.”
SEC filing →As of 2026
Sole-source dependency
- GM-CSF supplied by a single (unnamed) manufacturerhigh
Greenwich depends on a single manufacturer for its supply of GM-CSF (a key component of the GP2 immunotherapy) for ongoing clinical trials and any future commercialization.
“We will continue to be dependent on the manufacturer for our supply of GM-CSF in our ongoing GP2 clinical trials and upon potential commercialization of GP2.”
SEC filing →As of 2026
Key person
- Dependence on CEO Snehal Patel; no key-person insurancemedium
The company depends heavily on a small senior team led by Mr. Patel and carries no key-person life insurance, so loss of key personnel could derail development.
“We have not obtained, do not own, nor are we the beneficiary of, key-person life insurance.”
SEC filing →As of 2026
Other disclosures
- Related-party expense reimbursements to CEO and two family membersmedium
Expenses are incurred and reimbursed to CEO Snehal Patel and two family members contracted or employed by the company, with total reimbursements of ~$3.8M in 2025 (up from ~$1.8M in 2024) — a related-party governance concern for a pre-revenue company.
“The total reimbursements submitted for the full years ending December 31, 2025 and 2024 were approximately $ 3.8 million and $ 1.8 million , respectively.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Polypeptide Laboratories (San Diego, CA)
“The active pharmaceutical ingredient for our product candidate is currently sourced from Polypeptide Laboratories located in San Diego, California.”
Cited →Henry M. Jackson Foundation (HJF)
“The Henry M. Jackson Foundation out-licenses technology of the U.S. military and it conducts research and manages clinical trials.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch